Autoimmune Hepatitis Clinical Trials 2023

Autoimmune Hepatitis Clinical Trials 2023

Autoimmune Hepatitis research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in autoimmune hepatitis clinical trials today.

Autoimmune Hepatitis Clinical Trials

Here are the 6 most popular medical studies for autoimmune hepatitis

Popular filter options for autoimmune hepatitis trials

HCV Clinical Trials

View 24 HCV medical studies.

Non-alcoholic Fatty Liver Disease Clinical Trials

View 16 Non-alcoholic Fatty Liver Disease medical studies.

Phase 3 Autoimmune Hepatitis Clinical Trials

View 92 phase 3 autoimmune hepatitis medical studies.

Autoimmune Hepatitis Clinical Trials With No Placebo

View 92 autoimmune hepatitis medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to autoimmune hepatitis

What are the top hospitals conducting autoimmune hepatitis research?

When it comes to advancing the understanding and treatment of autoimmune hepatitis, several top hospitals are leading the way. In Boston, Massachusetts General Hospital takes center stage with five active clinical trials focused on this condition. This renowned institution is no stranger to groundbreaking research and has been making strides in autoimmune hepatitis since recording its first trial in 2016. Meanwhile, in Cleveland, the prestigious Cleveland Clinic is also actively involved in five ongoing trials for autoimmune hepatitis. Although they have not conducted any previous specific trials for this condition, their expertise and commitment to research make them an important player in the field.

Another significant contributor to autoimmune hepatitis research is the National Institutes of Health Clinical Center located in Bethesda. With four active clinical trials currently underway, this esteemed institution plays a crucial role in advancing our knowledge of this complex disease. Similarly, at Washington University School of Medicine in Saint Louis, researchers are conducting four active clinical trials while having accomplished one all-time trial focusing on autoimmune hepatitis since their inaugural study began just a few years ago.

Rounding out the list is UPMC (University of Pittsburgh Medical Center) where three cutting-edge clinical trials targeting autoimmune hepatitis are currently taking place. While they haven't conducted any previous studies dedicated solely to this condition yet holding immense potential as a highly regarded medical center specializing across various fields.

These hospitals represent beacons of hope for individuals living with autoimmune hepatitis by providing access to innovative treatments and contributing invaluable data that will ultimately shape future care approaches globally

Which are the best cities for autoimmune hepatitis clinical trials?

When it comes to autoimmune hepatitis clinical trials, several cities emerge as leading hubs for research and development. New york City boasts 38 ongoing trials focusing on various treatments like DUR-928 30 mg and BNT162b2. Boston, Massachusetts follows closely behind with 25 active studies exploring interventions such as DUR-928 30 mg and Rozanolixizumab. Miami, Florida, Houston, Texas, and Los Angeles, California also show promise with their respective numbers of active trials. These cities provide individuals with autoimmune hepatitis access to cutting-edge research opportunities that pave the way for improved treatment options and better outcomes in the future.

Which are the top treatments for autoimmune hepatitis being explored in clinical trials?

Autoimmune hepatitis is a complex condition, but researchers are actively exploring various treatments through clinical trials. Among the top contenders are:

  • Rituximab: 5 active trials, 93 all-time autoimmune hepatitis trials, first listed in 1997
  • Tofacitinib: 3 active trials, 36 all-time autoimmune hepatitis trials, first listed in 2011
  • Mycophenolate mofetil: 2 active trials for autoimmune hepatitis, involved in a total of 65 clinical studies since its introduction in the year2000.
What are the most recent clinical trials for autoimmune hepatitis?

Recent clinical trials have brought hope to individuals battling autoimmune hepatitis, as researchers explore new treatment options. One such trial focuses on the depletion of CD3/CD19 in an autologous stem cell transplant for autoimmune hepatitis. By targeting specific cells involved in the immune response, this approach aims to restore balance and alleviate symptoms. Another study examines the efficacy of HepB mAb19 administered intravenously for autoimmune hepatitis, evaluating its potential benefits in managing the condition. Additionally, Panzyga IVIG is being investigated as a potential therapy option, exploring its ability to modulate the immune system and improve liver function in patients with autoimmune hepatitis. These ongoing trials pave the way towards improved treatments that may enhance outcomes for those affected by this challenging condition.

What autoimmune hepatitis clinical trials were recently completed?

Recently completed clinical trials for autoimmune hepatitis have brought promising advancements in the field. Notably, a trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases investigated the efficacy of budesonide treatment, concluding in March 2021. Another significant milestone was reached when a trial exploring mycophenolate mofetil as a potential therapy was completed in January 2021. The completion of these trials underscores ongoing efforts to find effective treatments for autoimmune hepatitis and offers hope to patients affected by this challenging condition.